Literature DB >> 23560374

Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.

Kaid Darwiche1, Paul Zarogoulidis, Nikos K Karamanos, Kalliopi Domvri, Ekaterini Chatzaki, Theodoros C Constantinidis, Stylianos Kakolyris, Konstantinos Zarogoulidis.   

Abstract

Inhaled chemotherapy was first used more than 30 years ago. Since then, numerous chemotherapeutic agents have been used in either in vitro or in vivo studies. Several aspects of the methodology of the drug administration have been thoroughly demonstrated and explained. However, the safety concerns of these studies were not thoroughly investigated and different results regarding the same drug formulations have been reported. There are cases where the studies failed to demonstrate the long-term effects of the chemotherapeutic drug formulations to the lung parenchyma. Acute and latent effects observed in a small number of human trial studies are still under investigation of inhaled chemotherapy administration. This review provides data regarding all up-to-date inhaled chemotherapy studies and presents the methodological parameters of the safety measures incorporated. In addition, a commentary regarding the safety concerns for the medical staff participating in these studies will be presented.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560374     DOI: 10.2217/fon.12.205

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  14 in total

1.  Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.

Authors:  Haidong Huang; Paul Zarogoulidis; Sofia Lampaki; John Organtzis; Dimitris Petridis; Konstantinos Porpodis; Antonis Papaiwannou; Vasilis Karageorgiou; Georgia Pitsiou; Ioannis Kioumis; Wolfgang Hohenforst-Schmidt; Qiang Li; Kaid Darwiche; Lutz Freitag; Aggeliki Rapti; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model.

Authors:  James Verco; William Johnston; Michael Baltezor; Philip J Kuehl; Andrew Gigliotti; Steven A Belinsky; Anita Lopez; Ronald Wolff; Lauren Hylle; Gere diZerega
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-25       Impact factor: 2.849

3.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

Review 4.  Intensive care unit and lung cancer: when should we intubate?

Authors:  Paul Zarogoulidis; Athanasia Pataka; Eirini Terzi; Wolfgang Hohenforst-Schmidt; Nikolaos Machairiotis; Haidong Huang; Kosmas Tsakiridis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Andreas Mpakas; Kostas Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

5.  DDMC-p53 gene therapy with or without cisplatin and microwave ablation.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Joshua Stopek; Thomas Vogl; Frank Hübner; J Francis Turner; Robert Browning; Konstantinos Zarogoulidis; Antonis Drevelegas; Konstantinos Drevelegas; Kaid Darwiche; Lutz Freitag; Harald Rittger
Journal:  Onco Targets Ther       Date:  2015-05-20       Impact factor: 4.147

Review 6.  Clinical experimentation with aerosol antibiotics: current and future methods of administration.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Konstantinos Porpodis; Dionysios Spyratos; Kosmas Tsakiridis; Haidong Huang; Qiang Li; J Francis Turner; Robert Browning; Wolfgang Hohenforst-Schmidt; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2013-10-02       Impact factor: 4.162

7.  Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Helmut Teschler; Lonny Yarmus; Konstantinos Zarogoulidis; Lutz Freitag
Journal:  J Mol Genet Med       Date:  2013-08-26

8.  Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines.

Authors:  Antonios Sakkas; Paul Zarogoulidis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Dimitris Bougiouklis; Stylianos Kakolyris; Thomas Zarampoukas; Ioannis Kioumis; Georgia Pitsiou; Haidong Huang; Qiang Li; Soultana Meditskou; Theodora Tsiouda; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2014-04-17       Impact factor: 4.207

9.  Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Kaid Darwiche; Thomas Vogl; Eugene P Goldberg; Haidong Huang; Michael Simoff; Qiang Li; Robert Browning; Francis J Turner; Patrick Le Pivert; Dionysios Spyratos; Konstantinos Zarogoulidis; Seyhan I Celikoglu; Firuz Celikoglu; Johannes Brachmann
Journal:  Drug Des Devel Ther       Date:  2013-07-18       Impact factor: 4.162

10.  Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Bernd Linsmeier; Ioannis Kioumis; Qiang Li; Haidong Huang; Despoina Sachpatzidou; Sofia Lampaki; John Organtzis; Kalliopi Domvri; Leonidas Sakkas; George A Zachariadis; Konstantinos N Archontas; Anastasios Kallianos; Aggeliki Rapti; Lonny Yarmus; Konstantinos Zarogoulidis; Johannes Brachmann
Journal:  J Cancer       Date:  2014-03-24       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.